End-stage lung disease is caused by acute or chronic triggers, and patients eventually require a transplant. The DZL aims at improving the success rate of transplantation and is working intensively on the development of bridging therapies such as the extracorporeal membrane oxygenation (ECMO). ECMO is used temporarily, if still no suitable donor organ is available. An experimental research approach deals with the production of patient-specific tissue that could be used for replacement or regeneration in cases in which the lung tissue of a patient is damaged too much.